Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider Sales at Quantum, $QTM

Guest post by Benzinga:

Insiders have the most transparent view when valuing the company’s share price because they run the day-to-day business operations. This could provide a significant advantage to traders and investors when considering an investment opportunity. When Executives sell large stakes in their own company, are they losing confidence? This could be the case for Quantum (QTM).

Quantum Corp (NYSE:QTM)

Recent Inside Seller

QTM VP Barbara Barrett sold 101,056 shares on 6/3/11. Richard Belluzzo sold 451,752 shares on 6/3/11. This represents roughly a third of Mr. Belluzzo’s overall holdings. Considering that he is the Chairman of the Board, this fact should be noted and considered. Also, there has been a great deal of selling from insiders since the gap up in share price on April 13th. Mid-April through the present date represents a great deal of selling compared to any other point within the last 12 month time frame.

Technical Analysis

The stock is currently in a long-term uptrend that began in August 2010. The share price recently attempted a break of the gap down from early February. This attempt was unsuccessful. Current movement of share price justifies a move lower prior to any potential rally. The nearest support level would represent an 8%-10% correction. Considering the recent increase in selling from insiders, this could extend further.

Fundamental Analysis

Quantum Corp’s price-to-earnings ratio is higher than 99% of its competitors in the Computer Storage industry. The trailing twelve month P/E ratio is over 161x, meaning investors are willing to pay 161-times for the stock than what the company reports in earnings. As a growth stock with skyrocketing sales, a high P/E ratio is justified. This is not the case with Quantum. From 2008 to 2010, the company’s yearly revenues have decreased 12.2% and QTM’s year-over-year revenues for Q4 (the most recent quarter) have only grown by 0.3% or at a compounded quarterly rate of 0.1%. This does not justify its high P/E ratio.

Quantum’s year-over-year operating income for Q4 has fallen 87% or at a compounded quarterly rate of -40%.

Price-to-cash flow measures the market expectation of the company’s future financial well-being. Quantum’s price-to-cash flow is higher than 95% of its competitors in the Computer Storage industry. The trailing twelve month P/CF ratio is 23.7x, which means investors are willing to pay 23-times for the stock than what the company earns in cash flows. QTM’s year-over-year cash flow from operations for Q4 has fallen by 47% or at a compounded quarterly rate of -14.9%.

Management Efficiency

QTM’s return on assets is 0.97% over the last twelve months; this means that Quantum is able to see gains on its assets on par with its competitors. QTM’s year-over-year total asset growth for Q4 (the most recent quarter) has decreased by 14.5% or at a compounded quarterly rate of -3.8%.

Quantum’s current ratio is 1.02x. This states that QTM’s current assets are essentially the same as its current liabilities, which essentially means that the company could have difficulty paying its short-term liabilities. On the other hand, the company’s gross margin is 42%, which is slightly better than its competitors in the Computer Storage industry. This basically means EPIQ has more cash to spend on business operations than its competitors.

This article is originally published at Benzinga.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!